510(k) Report

510(k) · Cleared

Cleared

AP-2000, AP-2010, and AP-2020 Blood Glucose Monitoring System

K103116510(k) SpecialCleared Mar 13, 2012509-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bestgen Biotech Corp. · CGA Glucose Oxidase, Glucose

Cleared on Mar 13, 2012 as substantially equivalent to K090389 (Bestgen Biotech Corp., 2009) after a 509-day review. Its family tree reaches back 4 generations to 1997.

Decided
Mar 13, 2012
Review
509 days
Class
Class II
Product code
CGA
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to K964630 (1997). 5 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 4 generations backK964630 Glucometer Elite Blood Glucose MeterBayer Corp. · 1997
  2. 3 generations backK043311 Ascensia Elite Diabetes Care SystemBayer Healthcare, LLC · 2004
  3. 2 generations backK062538 Easy Check Blood Glucose Monitoring SystemDiacare Corp. · 2007
  4. 1 generation backK090389 AP-1000 Blood Glucose Monitoring SystemBestgen Biotech Corp. · 2009
  5. This deviceK103116 AP-2000, AP-2010, and AP-2020 Blood Glucose Monitoring SystemBestgen Biotech Corp. · 2012
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4K964630Glucometer Elite Blood Glucose MeterBayer Corp.1997—
−3K043311Ascensia Elite Diabetes Care SystemBayer Healthcare, LLC2004—
−2K062538Easy Check Blood Glucose Monitoring SystemDiacare Corp.2007—
−1K090389AP-1000 Blood Glucose Monitoring SystemBestgen Biotech Corp.2009—
0 (this device)K103116AP-2000, AP-2010, and AP-2020 Blood Glucose Monitoring SystemBestgen Biotech Corp.2012—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200210
FIG. 1 — Lineage of K103116, 1997–2012Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CGA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CGA device

  1. #1 K252488 ABL90 FLEX PLUS Systemscore 12.8 · 6 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K090389AP-1000 Blood Glucose Monitoring System
Summary page 4
…od Glucose Monitoring System. 5. Substantial Equivalence Informatian A. Predicate device name: AP-1000 Blood Glucose Monitoring System B. Predicate K number: k090389 C. Comparison with predicate: The modified AP-2000, AP-2000multi, AP-2010, AP-2Ol0multi, AP-2020, and AP-2O2Omulti Blood…
Bestgen Biotech Corp.2009—

Also cleared against K090389: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 15 years and passes through 4 companies; a new generation was cleared every 2.7 years on median.
  • None of the 5 ancestors has a recall.
  • 3 other devices also cite its predicate K090389.

How does its category compare?

All CGA devices

CGA Glucose Oxidase, Glucose: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.

FDA decisions per year · CGA

2in 2024

2007: 72008: 62009: 102010: 82011: 92012: 102013: 32014: 52015: 42016: 42017: 22018: 22019: 22020: 22021: 12022: 12023: 42024: 22026 (partial year): 1
2007high 10 (2009) · low 0 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGA

249in 2023

2007: 122 days median2008: 56 days median2009: 155 days median2010: 122 days median2011: 217 days median2012: 123 days median2013: 441 days median2014: 265 days median2015: 150 days median2016: 157 days median2023: 249 days median
2007high 441 (2013) · low 56 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CGA

3in 2023

2007: 22008: 22009: 42010: 62011: 32013: 32014: 22015: 6, 2 Class I2016: 22019: 12023: 3
2007high 6 (2010) · low 0 (2012)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · CGA

59in 2025

2007: 292008: 372009: 752010: 1722011: 4232012: 2332013: 1722014: 1222015: 1552016: 362017: 922018: 692019: 1162020: 682021: 482022: 2722023: 1,1412024: 2662025: 59
2007high 1,141 (2023) · low 29 (2007)2025

MAUDE reports naming product code CGA, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20077122229
2008656237
200910155475
201081226172
201192173423
2012101230233
201334413172
201452652122
201541506 (2)155
20164157236
20172—092
20182—069
20192—1116
20202—068
20211—048
20221—0272
2023424931,141
20242—0266
20250—059
20261—0—

What is it indicated for?

The AP-2000 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2000 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). it is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not…

Read the full statement (1,796 words)

The AP-2000 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2000 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). it is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2000 Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2000 Blood Glucose Test Strips must be used with the AP-2000 Meter. It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2000 Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2000 Blood Glucose Test Strips must be used the AP-2000 Blood Glucose Meter. It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution are for use with AP-2000 meter and AP-2000 Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

The AP-2000multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2000multi Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2000multi Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2000multi Blood Glucose Test Strips must be used with the AP-2000multi Meter. It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2000multi Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2000multi Blood Glucose Test Strips must be used the AP-2000multi Blood Glucose Meter. It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution is for use with AP-2000mullti meter and AP-2000multi Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

The A17-2010 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2010 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2010 Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2010 Blood Glucose Test Strips must be used with the AP-2010 Meter. It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2010 Blood Glucose Test Strips, are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2010 Blood Glucose Test Strips must be used the AP-2010 Blood Glucose Meter. It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution are for use with AP-2010 meter and AP-2010 Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

The AP-2Ol0multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2Ol0multi Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2Ol0multi Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2Ol0multi Blood Glucose Test Strips must be used with the AP-2Ol0multi Meter. It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2Ol0multi Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2Ol0multi Blood Glucose Test Strips must be used the AP-2Ol0multi Blood Glucose Meter. It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution is for use with AP-2Ol0multi meter and AP-2Ol0multi Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

The AP-2020 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2020 Blood Glucose Monitoring Systems is iiitended for testing outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2020 Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2020 Blood Glucose Test Strips must be used with the AP-2020 Meter. it is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2020 Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2020 Blood Glucose Test Strips must be used the AP-2020 Blood Glucose Meter. It is indicated for use at home (over the counter) [OTC] by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution are for use with AP-2020 meter and.AP-2020 Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

The AP-2OZ0multi Blood Glucose monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. The AP-2O2Omulti Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2O2Omulti Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2O2Omulti Blood Glucose Test Strips must be used with the AP-2Omulti Meter. It is intended for multi-patient use in 6 professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The AP-2O2Omulti Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger. AP-2O2Omulti Blood Glucose Test Strips must be used the AP-2O2Omulti Blood Glucose Meter. It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

MAJOR Level I/Level 11Control Solution is for use with AP-2Omulti meter and AP-2O2Oimulti Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K103116: AP-2000, AP-2010, and AP-2020 Blood Glucose Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K103116

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026